Search results for "AGENTS"

showing 10 items of 7330 documents

Effects of an Antimutagenic 1,4-Dihydropyridine AV-153 on Expression of Nitric Oxide Synthases and DNA Repair-related Enzymes and Genes in Kidneys of…

2016

Development of complications of diabetes mellitus (DM), including diabetic nephropathy, is a complex multi-stage process, dependent on many factors including the modification of nitric oxide (NO) production and an impaired DNA repair. The goal of this work was to study in vivo effects of 1,4-dihydropyridine AV-153, known as antimutagen and DNA binder, on the expression of several genes and proteins involved in NO metabolism and DNA repair in the kidneys of rats with a streptozotocin (STZ)-induced model of DM. Transcription intensity was monitored by means of real-time RT-PCR and the expression of proteins by immunohistochemistry. Development of DM significantly induced PARP1 protein express…

0301 basic medicineMalemedicine.medical_specialtyDihydropyridinesDNA RepairNitric Oxide Synthase Type IIIDNA repairPoly (ADP-Ribose) Polymerase-1Gene ExpressionNitric Oxide Synthase Type II030204 cardiovascular system & hematologyToxicologyKidneyNiacinStreptozocinNitric oxideDiabetes Mellitus ExperimentalDiabetic nephropathyHistones03 medical and health scienceschemistry.chemical_compound0302 clinical medicineEnosInternal medicineGene expressionmedicineAnimalsRNA MessengerRats WistarGenePharmacologybiologyReverse Transcriptase Polymerase Chain ReactionKidney metabolismAntimutagenic AgentsGeneral Medicinemedicine.diseaseStreptozotocinbiology.organism_classificationPhosphoproteinsMolecular biologyRats030104 developmental biologyEndocrinologychemistrymedicine.drugBasicclinical pharmacologytoxicology
researchProduct

Effects of social stress and clomipramine on emotional memory in mice.

2017

We have previously observed impairing effects of social defeat stress (CSDS) on inhibitory avoidance (IA) in mice. Given the similarity between changes produced by social stress in animals and symptoms of certain human psychopathologies such as depression and anxiety, the effects of the antidepressant clomipramine on IA impairment produced by CSDS were evaluated in the present study. Male CD1 mice were randomly assigned to the groups: non-stressed+saline, non-stressed+clomipramine, stressed+saline and stressed+clomipramine. Stressed animals were subjected to daily agonistic encounters (10 min) in the home cage of the aggressor over a 20-day period. Just before each encounter, non-stressed a…

0301 basic medicineMalemedicine.medical_specialtyElevated plus mazeClomipramineEmotionsAntidepressive Agents Tricyclicinhibitory avoidanceSocial defeat03 medical and health sciencesMice0302 clinical medicineEmotionalityMemoryInternal medicinemedicineAvoidance LearningReaction Timeelevated plus mazeAnimalsMaze LearningSocial stressAnalysis of Variancebusiness.industryGeneral NeuroscienceanalgesiaGeneral MedicineanxietyDisease Models AnimalInhibition Psychological030104 developmental biologyEndocrinologyClomipraminehot plateAntidepressantAnxietyAnalysis of variancemedicine.symptomlocomotor activitybusiness030217 neurology & neurosurgeryLocomotionStress Psychologicalchronic social defeat stressmedicine.drugActa neurobiologiae experimentalis
researchProduct

Anxiolytic effects of muscarinic acetylcholine receptors agonist oxotremorine in chronically stressed rats and related changes in BDNF and FGF2 level…

2017

Rationale: In depressive disorders, one of the mechanisms proposed for antidepressant drugs is the enhancement of synaptic plasticity in the hippocampus and cerebral cortex. Previously, we showed that the muscarinic acetylcholine receptor (mAChR) agonist oxotremorine (Oxo) increases neuronal plasticity in hippocampal neurons via FGFR1 transactivation. Objectives: Here, we aimed to explore (a) whether Oxo exerts anxiolytic effect in the rat model of anxiety-depression-like behavior induced by chronic restraint stress (CRS), and (b) if the anxiolytic effect of Oxo is associated with the modulation of neurotrophic factors, brain-derived neurotrophic factor (BDNF) and fibroblast growth factor-2…

0301 basic medicineMalemedicine.medical_specialtyElevated plus mazemedicine.drug_classBehavioral testPrefrontal CortexHippocampal formationAnxietyMuscarinic AgonistsAnxiolyticHippocampus03 medical and health sciences0302 clinical medicineInternal medicineMuscarinic acetylcholine receptormedicineOxotremorineMuscarinic acetylcholine receptor M4AnimalsElevated plus maze testRats WistarPrefrontal cortexmAChRChronic restraint streForced swimming testPharmacologyNeuronsChemistryBrain-Derived Neurotrophic FactorOxotremorineCerebral cortexRats030104 developmental biologymedicine.anatomical_structureEndocrinologyAnti-Anxiety AgentsCerebral cortexFibroblast Growth Factor 2Anxiety; Behavioral test; Cerebral cortex; Chronic restraint stress; Elevated plus maze test; Forced swimming test; mAChR; Neurotrophins; Novelty suppressed feeding test; PharmacologyNeurotrophinNovelty suppressed feeding testNeuroscience030217 neurology & neurosurgeryStress Psychologicalmedicine.drugPsychopharmacology
researchProduct

Glucagon-like peptide-2 reduces the obesity-associated inflammation in the brain.

2018

Growing evidence suggests a link between obesity and neurodegeneration. The purpose of the present study was to explore the neuroprotective potential of glucagon-like peptide-2 (GLP-2) in the brain of high fat diet (HFD)-fed mice. Markers of inflammation and oxidative stress were analysed in the brains of obese mice chronically treated with [Gly2]-GLP-2 (teduglutide), the stable analogue of the GLP-2, and they were compared to age-matched untreated obese and lean animals. Neurodegeneration was examined by TUNEL assay. HFD feeding increased the expression of pro-inflammatory mediators (NF-kB, IL-8, TNF-α, IL-1β and IL-6), glial fibrillary acidic protein (GFAP), index of gliosis and neurodege…

0301 basic medicineMalemedicine.medical_specialtyInflammationmedicine.disease_causeDiet High-FatSettore BIO/09 - FisiologiaNeuroprotectionlcsh:RC321-57103 medical and health sciences0302 clinical medicineNeuroinflammationInternal medicinemedicineGlucagon-Like Peptide 2AnimalsObesityNeurodegenerationlcsh:Neurosciences. Biological psychiatry. NeuropsychiatryNeuroinflammationTUNEL assayGlial fibrillary acidic proteinbiologyChemistryNeurodegenerationdigestive oral and skin physiologyBrainmedicine.diseaseMice Inbred C57BL030104 developmental biologyEndocrinologyNeuroprotective AgentsNeurologyGliosisOxidative stressAstrocytesbiology.proteinGlucagon-Like Peptide-2 ReceptorOxidative streEncephalitismedicine.symptomInflammation MediatorsGLP-2030217 neurology & neurosurgeryOxidative stresshormones hormone substitutes and hormone antagonistsNeurobiology of disease
researchProduct

Emergent Uric Acid Treatment is Synergistic with Mechanical Recanalization in Improving Stroke Outcomes in Male and Female Rats.

2018

Preclinical and clinical studies support a promising, albeit not definitive, neuroprotective effect of emergent uric acid (UA) administration in ischemic stroke. We assessed the effects of UA in an ischemic stroke model relevant to the current treatment paradigm of mechanical thrombectomy within the STAIR/RIGOR recommendations. A cohort of male and female Wistar rats was subjected to ischemic stroke with mechanical recanalization under physiological monitoring. The effects of transient middle cerebral artery occlusion (tMCAO) with adjunctive UA (IV, 16 mg/kg) or vehicle treatment were assessed at 24 h and 7 days. Outcomes included neurofunctional impairment, brain infarct (TTC staining, MRI…

0301 basic medicineMalemedicine.medical_specialtyMechanical ThrombolysisBrain damageNeuroprotectionBrain Ischemia03 medical and health sciencesCresyl violetchemistry.chemical_compoundRandom Allocation0302 clinical medicineuric acidInternal medicineEdemamedicineischemic strokeAnimalsRats WistarStrokebusiness.industryGeneral Neurosciencerat modeladjunctive treatmentBrainRecovery of Functionmedicine.diseaseCombined Modality TherapyUric AcidStrokeDisease Models Animal030104 developmental biologyNeuroprotective AgentschemistrythrombectomyAdjunctive treatmentIschemic strokeCardiologyUric acidneuroprotectionFemalemedicine.symptombusiness030217 neurology & neurosurgeryNeuroscience
researchProduct

How do skeletal morbidity rate and special toxicities affect 12-week versus 4-week schedule zoledronic acid efficacy? A systematic review and a meta-…

2019

Abstract Background Zoledronic Acid is a bisphosphonate used in a 4-week schedule for the treatment of bone metastases. Some randomized trials supported its role also when administered every 12 weeks. Methods we performed a systematic review and a meta-analysis in order to evaluate the two different schedules in terms of skeletal morbidity rate (SMR), skeletal related events (SRE) and adverse events (AEs). Results our results showed a clinical difference favouring the 12-week schedule in terms of AEs (RR 1.17, 95% CI 1.06–1.29). No signifcant differences were found for SMR (RR 0.97, 95% CI 0.84–1.13) and SRE (RR 1.02, 95% CI 0.89–1.16). Conclusions Our findings support in clinical practice …

0301 basic medicineMalemedicine.medical_specialtyMeta-AnalysiBone Density Conservation Agentmedicine.medical_treatmentBone NeoplasmsBreast NeoplasmsBone NeoplasmZoledronic Acidlaw.invention03 medical and health sciencesProstate cancer0302 clinical medicineRandomized controlled triallawInternal medicinemedicineHumansHypocalcaemiaBreastAdverse effectBone Density Conservation AgentsSolid tumorbusiness.industryMortality rateProstateProstatic NeoplasmsAEHematologyBisphosphonateSMRmedicine.diseaseBone metastase030104 developmental biologyZoledronic acidTreatment OutcomeOncology030220 oncology & carcinogenesisMeta-analysisProstatic NeoplasmFemalebusinessBreast Neoplasmmedicine.drugHuman
researchProduct

Recombinant human hepatocyte growth factor provides protective effects in cerulein-induced acute pancreatitis in mice.

2018

Acute pancreatitis is a multifactorial disease associated with profound changes of the pancreas induced by release of digestive enzymes that lead to increase in proinflammatory cytokine production, excessive tissue necrosis, edema, and bleeding. Elevated levels of hepatocyte growth factor (HGF) and its receptor c-Met have been observed in different chronic and acute pancreatic diseases including experimental models of acute pancreatitis. In the present study, we investigated the protective effects induced by the recombinant human HGF in a mouse model of cerulein-induced acute pancreatitis. Pancreatitis was induced by 8 hourly administrations of supramaximal cerulein injections (50 µg/kg, ip…

0301 basic medicineMalemedicine.medical_specialtyNecrosisPhysiologyClinical BiochemistryInflammationApoptosismedicine.disease_causeProtective AgentsAntioxidantsProinflammatory cytokine03 medical and health sciencesMiceInternal medicineEdemamedicineAnimalsHumansbusiness.industryHepatocyte Growth FactorCell BiologyProto-Oncogene Proteins c-metmedicine.diseaseGlutathioneSurvival AnalysisRecombinant ProteinsDisease Models AnimalOxidative Stress030104 developmental biologyEndocrinologyPancreatitisAcute pancreatitisPancreatitisHepatocyte growth factormedicine.symptombusinessOxidative stressCeruletidemedicine.drugSignal TransductionJournal of cellular physiology
researchProduct

Loop diuretics decrease the renal elimination rate and increase the plasma levels of trimethylamine‐N‐oxide

2018

Aims Trimethylamine-N-oxide (TMAO) is a novel cardiovascular risk marker. We explored the association of commonly used cardiovascular medications with TMAO levels in patients and validated the identified associations in mice. Methods Detailed history of drug treatment was recorded in 300 patients with cardiovascular disease without diabetes in an observational, cross-sectional study. Animal study was performed in CD1 mice. Results Median plasma TMAO (interquartile range) level was 2.144 (1.570-3.104) μmol l-1 . Among nine cardiovascular drug groups, the use of loop diuretics (0.510 ± 0.296 in users vs. 0.336 ± 0.272 in nonusers, P = 0.008) and mineralocorticoid receptor antagonists (0.482 ±…

0301 basic medicineMalemedicine.medical_specialtyOrganic anion transporter 1medicine.drug_classTrimethylamine N-oxide030204 cardiovascular system & hematologyKidneyExcretion03 medical and health scienceschemistry.chemical_compoundMethylaminesMice0302 clinical medicineSodium Potassium Chloride Symporter InhibitorsInternal medicineBlood plasmamedicineAnimalsHumansPharmacology (medical)AgedPharmacologybiologyChemistryArea under the curveFurosemideCardiovascular AgentsHeartOriginal ArticlesLoop diureticMiddle AgedProbenecid030104 developmental biologyEndocrinologyCross-Sectional StudiesLiverCardiovascular Diseasesbiology.proteinFemaleBiomarkersmedicine.drug
researchProduct

Effect of chondroitin sulphate on synovitis of knee osteoarthritic patients.

2017

Abstract Objective To evaluate by ultrasonography the effect of chondroitin sulfate (CS) on synovitis in patients with knee osteoarthritis (KOA). To collaborate in the understanding of the biochemical mechanisms involved in the synovial inflammation process. Methods Randomized, single-blind, controlled trial involving 70 patients with primary KOA treated for 6 months with CS or acetaminophen (ACT). Evaluation of KOA status at baseline, 6 weeks, 3 and 6 months included: ultrasonography to assess synovitis (following the OMERACT expertise group definition), visual analogue scale and Lequesne index to measure pain and function, and ELISA to quantify inflammatory mediators in serum and synovial…

0301 basic medicineMalemedicine.medical_specialtyVisual analogue scaleInflammationPilot ProjectsOsteoarthritisGastroenterologylaw.invention03 medical and health scienceschemistry.chemical_compound0302 clinical medicineRandomized controlled triallawInternal medicineSynovitisMedicineSynovial fluidHumansSingle-Blind MethodChondroitin sulfateAcetaminophenAgedPain MeasurementUltrasonography030203 arthritis & rheumatologyAged 80 and overSynovitisbusiness.industryAnti-Inflammatory Agents Non-SteroidalChondroitin SulfatesMiddle AgedOsteoarthritis Kneemedicine.diseaseAcetaminophenBiomechanical Phenomena030104 developmental biologyTreatment OutcomechemistryFemalemedicine.symptombusinessBiomarkersmedicine.drugFollow-Up StudiesMedicina clinica
researchProduct

Endothelial GLP-1 (Glucagon-Like Peptide 1) Receptor Mediates Cardiovascular Protection by Liraglutide In Mice With Experimental Arterial Hypertension

2019

Supplemental Digital Content is available in the text.

0301 basic medicineMalemedicine.medical_specialtyhypertensionBlotting WesternInflammationBlood Pressure030204 cardiovascular system & hematologyangiotensin IImedicine.disease_causeGlucagon-Like Peptide-1 Receptor1005403 medical and health sciencesMice0302 clinical medicine10030Internal medicinemedicineoxidative stressAnimalsHypoglycemic AgentsReceptor10111Cells CulturedMice KnockoutliraglutideLiraglutidebusiness.industryBasic SciencesType 2 Diabetes MellitusEndothelial CellsAtherosclerosisGlucagon-like peptide-1Angiotensin II3. Good healthMice Inbred C57BLDisease Models Animal030104 developmental biologyEndocrinology10040inflammationComputingMethodologies_DOCUMENTANDTEXTPROCESSINGRNAmedicine.symptomCardiology and Cardiovascular Medicinebusiness10024Oxidative stressmedicine.drug
researchProduct